Press release
Parkinson's Disease Psychosis Pipeline Insight Report 2023 (Updated) | Vanda Pharmaceuticals, Sumitomo Pharma, ACADIA Pharmaceuticals Inc., Otsuka America Pharmaceutical, and others.
Parkinsons Disease Psychosis Pipeline
In the Parkinson's Disease Psychosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Parkinson's disease psychosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
To explore more information on the latest breakthroughs in the Parkinson's disease Psychosis Pipeline treatment landscape of the report, click here @ Parkinson's Disease Psychosis Pipeline Outlook- https://www.delveinsight.com/report-store/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Parkinson's Disease Psychosis Pipeline Report
• DelveInsight's Parkinson's Disease Psychosis Pipeline analysis depicts a robust space with 5+ active players working to develop 5+ pipeline treatment therapies.
• The leading companies are working in the Parkinson's Disease Psychosis market include Vanda Pharmaceuticals, Sumitomo Pharma, ACADIA Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Axovant Sciences Ltd., Anavex Life Sciences Corp., and others.
• Promising Parkinson's Disease Psychosis Pipeline Therapies in the various stages of development include SEP-363856, Iloperidone, Pimavanserin, aripiprazole, and others.
• On Februray 2023, Annovis Bio Inc announced a study of phase 1 & 2 clinical trials for Posiphen. Annovis is conducting a clinical study to investigate Posiphen in patients with Early Alzheimer's Disease (AD) and Early Parkinson's Disease (PD).
• On May 2023, Stanford University announced a study of phase 4 clinical trials for Sodium Oxybate. This study is the first clinical trial using sodium oxybate for the treatment of REM sleep behavior disorder (RBD). Sodium oxybate is a drug approved by FDA for the treatment of narcolepsy which has been used "off label" to treat patients with severe RBD. This drug has shown to be effective and well tolerated in patients with RBD (Shneerson, 2009; Liebenthal, 2016; Moghadam, 2017).
Parkinson's Disease Psychosis Overview
Nonmotor symptoms have an important impact on quality of life in PD patients and their caregivers and are largely recognized as such by a growing number of health care providers. Psychosis is recognized as one of the most frequent and disabling nonmotor symptoms in PD with prevalences of 20% up to 70% in advanced stages of the condition.
For further information, refer to the detailed Parkinson's Disease Psychosis Unmet Needs, click here for Parkinson's Disease Psychosis Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Parkinson's Disease Psychosis Emerging Drugs Profile
• Iloperidone: Vanda Pharmaceuticals
Iloperidone belongs to a class of medications for schizophrenia known as atypical antipsychotics. Acceptance of the NDA application confirms that the application is sufficiently complete for FDA review for the treatment of schizophrenia.
• Ulotaront: Sumitomo Pharma
Ulotaront (SEP-363856) is a trace amine-associated receptor 1 (TAAR1) agonist with serotonin 5-HT1A agonist activity, jointly developed by Sunovion and PsychoGenics Inc, which is a small-molecule oral agent that does not bind to dopamine D2 or serotonin 5-HT2A receptors. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for ulotaront for the treatment of schizophrenia in May 2019.
Parkinson's Disease Psychosis Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies Parkinson's disease psychosis. The Parkinson's Disease Psychosis companies which have their Parkinson's disease psychosis drug candidates in the most advanced stage, i.e phase II include Vanda Pharmaceuticals.
Request a sample and discover the recent advances in Parkinson's Disease Psychosis Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Parkinson's Disease Psychosis Segmentation- https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Parkinson's Disease Psychosis Drugs and Companies
• SEP-363856: Sumitomo Pharma America Inc.
• Iloperidone: Vanda Pharmaceuticals
• Pimavanserin: Acadia Pharmaceuticals Inc.
Parkinson's Disease Psychosis Therapeutics Assessment
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Some of the Companies in the Parkinson's Disease Psychosis Therapeutics Market include-
Vanda Pharmaceuticals, Sumitomo Pharma, ACADIA Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Axovant Sciences Ltd., Anavex Life Sciences Corp., and others.
Dive deep into rich insights for drugs for Parkinson's Disease Psychosis Pipeline, click here @ Parkinson's Disease Psychosis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Parkinson's Disease Psychosis Pipeline Report
• Coverage- Global
• Companies- Vanda Pharmaceuticals, Sumitomo Pharma, ACADIA Pharmaceuticals Inc., Otsuka America Pharmaceutical, Lundbeck LLC, Jazz Pharmaceuticals, Alkahest Inc., Sandoz, Axovant Sciences Ltd., Anavex Life Sciences Corp., and others.
• Therapies- SEP-363856, Iloperidone, Pimavanserin, aripiprazole, and others.
• Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Parkinson's Disease Psychosis Merger and acquisitions, Licensing Activities- https://www.delveinsight.com/sample-request/parkinsons-disease-psychosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Parkinson's disease psychosis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Parkinson's disease psychosis- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Iloperidone: Vanda Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug name: Company name
15. Drug profiles in the detailed report…..
16. Preclinical Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Parkinson's disease psychosis Key Companies
21. Parkinson's disease psychosis Key Products
22. Parkinson's disease psychosis- Unmet Needs
23. Parkinson's disease psychosis- Market Drivers and Barriers
24. Parkinson's disease psychosis- Future Perspectives and Conclusion
25. Parkinson's disease psychosis Analyst Views
26. Parkinson's disease psychosis Key Companies
27. Appendix
Important Published Links
https://logcworld.mn.co/posts/46134506
https://marketingops.mn.co/posts/46134636
https://motorcycle-events.mn.co/posts/46134899
https://intuitive-schooling.mn.co/posts/46135011
https://plenty-of-heathens.mn.co/posts/advancements-and-market-trends-in-langerhans-cell-histiocytosis-treatment
https://shopsanity.mn.co/posts/understanding-the-langerhans-cell-histiocytosis-market-current-landscape-and-future-prospects
https://mccoterie.mn.co/posts/46135751
https://go02100.mn.co/posts/46136119
https://freesaloneducation.mn.co/posts/46136215
https://sokomtaani.mn.co/posts/46136615
https://skillcrush.mn.co/posts/46136691
https://advicehonest.mn.co/posts/46136795
https://evening-newss.mn.co/members/20271728
https://omind.mn.co/members/20271735
https://shop1606.mn.co/posts/45816438
https://council-of-light.mn.co/posts/45816468
https://chanspirations.mn.co/posts/45816726
https://hulu-com-forgot.mn.co/posts/45816832
https://bucketseems-news.mn.co/members/20271966
https://sentinels.mn.co/members/20272156
https://akademe.mn.co/posts/navigating-the-acne-vulgaris-market-trends-treatments-and-technological-advances
https://tc-2345.mn.co/posts/45818004
https://gene-keys-genealogy.mn.co/posts/45818150
https://take-your-phone.mn.co/posts/45818381
https://digitaldrip.mn.co/posts/45818561
https://network-24921.mn.co/posts/45818644
https://friends-of-zizira.mn.co/members/20272206
https://brooklynneo.mn.co/posts/45404495
https://ucat-bootcamp.mn.co/posts/45404540
https://coding-playground.mn.co/posts/45404600
https://living-word-network.mn.co/posts/45404653
https://treadmill.mn.co/posts/45459156
https://chineseintheus.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast
https://wear.net/dennydones9/
https://productinn.mn.co/posts/parkinsons-disease-market-outlook-and-forecast-report-2032
https://justchatting.mn.co/posts/45460636
https://expressyourcurve.mn.co/posts/45460860
https://clinalleve.mn.co/posts/parkinsons-disease-market-size-outlook-and-forecast-2032
https://nhattao.com/members/user6331540.6331540/
https://seedly.sg/profile/denny-dones/
https://note.com/denny_dones/n/n489e5dd1ff1a
https://www.uplabs.com/dennydones9
https://www.zazzle.com/mbr/238605385879691977
https://independent.academia.edu/HavenSmith2
https://play.eslgaming.com/player/19736877/
https://creators.audiomack.com/dennydones1
https://piano.masto.host/@dennydones9
https://tech4goodwales.mn.co/posts/the-evolving-landscape-of-the-major-depressive-disorder-market
https://worldletinews.mn.co/members/20156129
https://community.greeka.com/users/dennydones9
https://www.exchangle.com/dennydones9
https://old.meneame.net/user/dennydones9
https://gsap.com/community/profile/159086-denny-dones/
https://www.pling.com/u/dennydones9/
https://shaunbook.mn.co/posts/type-1-diabetes-market-size-forecast-and-outlook-2032
https://zip-launchpad.mn.co/posts/45579349
https://dj-club-sf.mn.co/posts/45579415
https://wwwpreparatorianis.mn.co/posts/45579543
https://www.projectnoah.org/users/dennydones9
https://naijases.mn.co/posts/type-1-diabetes-market-future-trends-and-opportunities
https://indicate.mn.co/posts/45580238
https://linkasia.mn.co/posts/45580415
https://playhq.mn.co/posts/45580609
https://coco-quinn.mn.co/posts/45580757
https://aeros.mn.co/posts/45751762
https://churecipe.mn.co/posts/45751826
https://itravel.mn.co/members/20248979
https://hubvin.mn.co/posts/45752020
https://drujrake.mn.co/posts/45752126
https://together.mn.co/posts/45752522
https://bipolarjungle.mn.co/posts/45752571
https://mossfon.mn.co/posts/45752666
https://create-lifestyle.mn.co/posts/45753329
https://gelardas.mn.co/members/20249381
https://bloby.mn.co/posts/45753578
https://cic-mun.mn.co/posts/45753710
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Parkinson's Disease Psychosis Pipeline Insight Report 2023 (Updated) | Vanda Pharmaceuticals, Sumitomo Pharma, ACADIA Pharmaceuticals Inc., Otsuka America Pharmaceutical, and others. here
News-ID: 3311979 • Views: …
More Releases from DelveInsight Business Research LLP
Oncolytic Virus Cancer Therapy Market | Companies involved: Targovax, Replimune, …
DelveInsight's "Oncolytic Virus Cancer Therapy Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Oncolytic Virus Cancer Therapy, historical and forecasted epidemiology as well as the Oncolytic Virus Cancer Therapy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Oncolytic Virus Cancer Therapy market report provides current treatment practices, emerging drugs, Oncolytic Virus Cancer Therapy market share of the…
Lymphocytopenia Market to Witness Growth | AbbVie Inc, BristolMyersSquibb, CSL L …
DelveInsight's "Lymphocytopenia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Lymphocytopenia, historical and forecasted epidemiology as well as the Lymphocytopenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Lymphocytopenia market report provides current treatment practices, emerging drugs, Lymphocytopenia market share of the individual therapies, and current and forecasted Lymphocytopenia market size from 2019 to 2032 segmented by…
Complex Regional Pain Syndrome Market to Witness Growth by 2032 |Ovid therapeuti …
DelveInsight's "Complex Regional Pain Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Complex Regional Pain Syndrome, historical and forecasted epidemiology as well as the Complex Regional Pain Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Complex Regional Pain Syndrome market report provides current treatment practices, emerging drugs, Complex Regional Pain Syndrome market share of the…
Meningitis Market to Witness Growth by 2032 | Bausch Health Companies Inc., Myla …
DelveInsight's "Meningitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Meningitis, historical and forecasted epidemiology as well as the Meningitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Meningitis market report provides current treatment practices, emerging drugs, Meningitis market share of the individual therapies, and current and forecasted Meningitis market size from 2019 to 2032 segmented by…
More Releases for Parkinson
QualitySolicitors Parkinson Wright invest in the future
QualitySolicitors Parkinson Wright has selected Liberate from Linetime as its business-wide legal services software platform. The Worcestershire based practice, with over 100 staff, operate from 4 offices and have a highly regarded reputation for their services including residential property, private client, family, dispute resolution and commercial. The firm also has its own estate agency.
The firm recognised that to continue delivering high quality services to its clients it needed to provide…
Wolff Parkinson White syndrome Market found Future opportunities of 2023
The Analysis presents the study of Global Wolff Parkinson White syndrome Market facilitating the regional and country wise analysis covering the strategic analysis of each market player and the market share they hold
Wolff Parkinson White Syndrome Market Information: By Types (Type A, Type B) By Diagnosis (Electrocardiogram (ECG), Electrophysiological Testing, Others) By Treatment (Drugs (Anti-Arrhythmic, Beta-Blockers, Others), Cardioversion, Radiofrequency Catheter Ablation, Surgery, Artificial Pacemaker, Others) By End Users - Global…
PARKINSON RESEARCH FOUNDATION Announces Director of Patient Programs, Services a …
The Parkinson Research Foundation is pleased to announce that Marilyn Tait has joined the foundation as the Director of Patient Programs, Services and Advocacy. Tait, is a graduate of Thomas Jefferson University School of Nursing in Philadelphia, Pennsylvania. Tait has forty years experience in healthcare marketing and program development. After specializing in oncology for 30 years, Tait embarked on her new career at a time in her life when…
PARKINSON RESEARCH FOUNDATION’S (PRF) WESTERN CARIBBEAN FOURTH EDUCATIONAL CRU …
The Parkinson Research Foundation (PRF), a non-profit organization with a dedicated patient education program, will return to the Western Caribbean for its fourth educational cruise. PRF developed its educational cruise program to give Parkinson patients, caregivers family and loved ones unrivaled access to experts in the movement-disorder field.
After visiting the Bahamas and Alaska on the first two respective PRF cruises, PRF’s ventured to the Western Caribbean on its most…
PARKINSON RESEARCH FOUNDATION (PRF) Develops New Patient Outreach Program
One of the principal missions of the Parkinson Research Foundation (PRF) that distinguishes it from other Parkinson organizations is PRF’s focus on patient education; specifically education that enables Parkinson patients and their caregivers to live fuller and more comfortable lives with Parkinson's disease.
The Foundation’s educational events, including educational cruises, gather leading Parkinson experts, therapists and nutritionists from across the country to offer life-changing tools and knowledge for individuals affected…
Parkinson`s Disease:New Hope Educational Conference
PARKINSON’S DISEASE: NEW HOPE EDUCATIONAL CONFERENCE
Become knowledgeable about the advancements in surgery
The Parkinson Research Foundation is proud to announce that Dr. James Schumacher will be speaking about advances in surgery at our fourth annual New Hope for Parkinson’s conference on November 1st in Boca Raton. Dr. Schumacher is an internationally known expert in the field of neurosurgical treatment of Parkinson’s disease and movement disorders. He has an extensive background and…
